CARM vs. MURA, MNOV, KRON, EQ, VHAQ, ALRN, EGRX, KZR, CKPT, and DERM
Should you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Mural Oncology (MURA), MediciNova (MNOV), Kronos Bio (KRON), Equillium (EQ), Viveon Health Acquisition (VHAQ), Aileron Therapeutics (ALRN), Eagle Pharmaceuticals (EGRX), Kezar Life Sciences (KZR), Checkpoint Therapeutics (CKPT), and Journey Medical (DERM). These companies are all part of the "pharmaceutical preparations" industry.
Carisma Therapeutics (NASDAQ:CARM) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment.
Carisma Therapeutics currently has a consensus price target of $8.60, indicating a potential upside of 481.08%. Mural Oncology has a consensus price target of $13.00, indicating a potential upside of 243.92%. Given Carisma Therapeutics' higher probable upside, research analysts clearly believe Carisma Therapeutics is more favorable than Mural Oncology.
In the previous week, Carisma Therapeutics had 9 more articles in the media than Mural Oncology. MarketBeat recorded 13 mentions for Carisma Therapeutics and 4 mentions for Mural Oncology. Mural Oncology's average media sentiment score of 0.19 beat Carisma Therapeutics' score of -0.09 indicating that Mural Oncology is being referred to more favorably in the news media.
44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 80.2% of Mural Oncology shares are owned by institutional investors. 17.0% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Mural Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Mural Oncology has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -538.81%. Mural Oncology's return on equity of 0.00% beat Carisma Therapeutics' return on equity.
Carisma Therapeutics received 10 more outperform votes than Mural Oncology when rated by MarketBeat users.
Carisma Therapeutics has higher revenue and earnings than Mural Oncology.
Summary
Carisma Therapeutics beats Mural Oncology on 7 of the 12 factors compared between the two stocks.
Get Carisma Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Carisma Therapeutics Competitors List
Related Companies and Tools
